Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel-MedSci.cn

Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel

Alvarez-Lopez, I; Gonzalez, E; Manso, LM; Alonso, JL; Cruz-Hernandez, JJ; Ballerini, VC; Gallegos, I; Varela, MQ; Illaramendi, JJ; Vicente, E; Garcia, AIB; de la Pena, FA; Perello, A; Vidal, J; Cussac, AL

ANNALS OF ONCOLOGY, 2020; 31 (): S29

科室
- - 订阅+
  - 更多科室
工具
服务